Last updated: March 14, 2026
What Are the Key Criteria for Patentability of Biopharmaceuticals in Paraguay?
Patent examiners in Paraguay evaluate biopharmaceutical patent applications based on international standards aligned with the Patent Law No. 1,753/2000. The core criteria include novelty, inventive step (non-obviousness), industrial applicability, and compliance with formal requirements.
Novelty:
An application must demonstrate that the invention is new. Publicly disclosed data, prior inventions, or existing patents in Paraguay or abroad can jeopardize novelty. There is no grace period; disclosures before filing render the invention unpatentable.
Inventive Step:
The invention must not be obvious to a person skilled in the field. In biopharmaceuticals, this criterion often hinges on whether the claimed invention provides a significant technical improvement over existing solutions.
Industrial Applicability:
The invention must have a practical use or be capable of being produced and used in manufacturing.
Patentability Exceptions:
Officially excluded are diagnostic methods, methods of treatment, and plant or animal varieties. However, purified or isolated biopharmaceutical molecules may qualify if they meet patent criteria.
How Is Patent Enforceability Assessed in Paraguay?
Enforceability depends on the patent's validity and the rights conferred. Once granted, a patent in Paraguay provides a monopoly period of 20 years from the filing date.
Key enforceability considerations include:
-
Patent Rights:
The owner can prevent third parties from manufacturing, using, or selling the patented biopharmaceutical without authorization.
-
Infringement Actions:
Legal remedies include injunctions, damages, and potential penalties for unauthorized manufacturing or commercialization.
-
Validity Challenges:
Third parties may initiate nullity proceedings within five years from grant, claiming errors in examination or failure to meet patentability criteria.
-
Compulsory Licensing:
Paraguay permits compulsory licenses in cases of national emergency, non-working, or public interest, under conditions specified in Law No. 1,753/2000 and international agreements like TRIPS.
What Is the Scope of Claims for Biopharmaceutical Patents?
The scope depends on how the claims are drafted, balancing breadth with defensibility. Paraguayan practice favors specific claims covering molecules, compositions, methods of production, and therapeutic uses.
Claim Types:
-
Compound Claims: Cover the isolated substance, e.g., a specific protein or biologic molecule.
-
Method Claims: Cover processes for manufacturing or using the biopharmaceutical.
-
Use Claims: Protect specific therapeutic applications.
Claim Language:
Claims must be clear, concise, and supported by the description. Broad claims covering structural similarities or functional equivalents must be justified with detailed description to withstand validity challenges.
Scope Limitations:
Claims that attempt to cover basic or known biopharmaceuticals without establishing novelty or inventive step are vulnerable to invalidity proceedings.
Summary of Key Data
| Aspect |
Details |
| Patent Term |
20 years from the filing date |
| Patent Examination Policy |
Aligns with international standards (e.g., TRIPS) |
| Filing Requirements |
Patent application, detailed description, claims, drawings |
| Priority Claims |
Allowed if filed within 12 months of initial application |
| Enforcement Period |
Post-grant, enforceable through legal actions |
Principal Challenges in Paraguay
-
Novelty and Inventive Step:
Given limited local prior art, examiners focus on international disclosures. However, inventive step remains a critical hurdle, especially for incremental biopharmaceutical innovations.
-
Scope of Claims:
Overly broad claims risk invalidation; narrow claims are easier to defend.
-
Enforcement Resources:
Legal procedures can be lengthy, with limited specialized enforcement mechanisms for complex biopharmaceutical infringement cases.
Legal Developments:
Paraguay adopted amendments to align with the Anti-Patent Evergreening provisions, discouraging overly broad or secondary patent claims that could extend exclusivity improperly.
Key Takeaways
- Biopharmaceutical patentability in Paraguay hinges on meeting novelty, inventive step, and industrial application standards, with strict scrutiny applied to broad claims.
- Patent enforceability relies on maintaining validity, with enforcement options accessible through civil litigation, but procedural delays and resource limitations may hinder swift action.
- Drafting scope should balance broad protection with detailed claims supported by evidence to withstand validity challenges.
- Consider international treaties like TRIPS, which Paraguay implements, to understand rights and limitations.
- Regularly monitor legal updates and case law to adjust patent strategies accordingly.
FAQs
1. Can naturally occurring molecules be patented in Paraguay?
Only if isolated, purified, or modified to demonstrate a specific new function or property not evident in nature.
2. Are method-of-treatment patents allowed for biopharmaceuticals?
Yes, if the method involves novel, non-obvious steps, but the patentability of treatment methods is typically limited, especially for medical procedures.
3. How does Paraguay treat patent term extensions for biopharmaceuticals?
No specific extension provisions; patents secure 20 years from filing, subject to timely maintenance payments.
4. What is the impact of international agreements on Paraguayan biopharmaceutical patents?
Treaties like TRIPS influence patent standards and enforcement; Paraguay’s laws incorporate TRIPS provisions directly.
5. Are compulsory licenses common for biopharmaceuticals?
Rare, but permissible under law and international obligations, especially in cases of non-working or public health emergencies.
References
[1] Paraguayan Patent Law No. 1,753/2000.
[2] World Trade Organization. Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
[3] WIPO. Overview of Patent Laws in Latin America.
[4] UNCTAD. Intellectual Property Rights and Access to Medicines in Developing Countries.
[5] Paraguayan National Patent Office (DINAPI). Official Guidelines and Procedures.
